Effects of the?-glucosidase inhibitor 1 desoxynojirimycin (BAY M 1099) on postprandial blood glucose, serum insulin and C-peptide levels in type II diabetic patients

1986 ◽  
Vol 30 (4) ◽  
pp. 417-419 ◽  
Author(s):  
Ch. Schnack ◽  
G. R�ggla ◽  
A. Luger ◽  
G. Schernthaner
Keyword(s):  
Blood Glucose ◽  
Serum Insulin ◽  
Postprandial Blood Glucose ◽  
Diabetic Patients ◽  
Type Ii ◽  
C Peptide ◽  
Glucosidase Inhibitor

scholarly journals Adipose-Derived Mesenchymal Stem Cells for Treatment Tertiary Failure Diabetes Mellitus Type 2

2017 ◽  
Vol 31 ◽  
pp. 91-95 ◽  
Author(s):  
Purwati ◽  
Sony Wibisono ◽  
Ari Sutjahjo ◽  
T.J. Askandar ◽  
Fedik Abdul Rantam
Keyword(s):  
Diabetes Mellitus ◽  
Stem Cells ◽  
Mesenchymal Stem Cells ◽  
Blood Glucose ◽  
Diabetes Mellitus Type 2 ◽  
Diabetes Mellitus Type ◽  
Postprandial Blood Glucose ◽  
Diabetic Patients ◽  
C Peptide

Recent progress in diabetes mellitus therapy has focused attention on generation of surrogate β-cells from mesenchymal stem cells (MSCs) derived adult tissues. In this study, we conducted a phase I clinical trial in patients with type 2 diabetes mellitus in various age between 30-79 years old who were treated with autologous adipose-derived MSCs transplantation. MSCs injected into diabetic patients through catheterization then we measured levels of fasting blood glucose, 2h postprandial blood glucose, insulin, c-peptide pre and post stem cell transplantation, also HbA1c. Levels of blood glucose (fasting and 2h post prandial) and insulin were absolutely decreasing after injection. Meanwhile, level of c-peptide was increasing after injection. Level of HbA1c was significantly decreasing after 3 months injection. Thus, adipose-derived mesenchymal stem cells for treatment tertiary failure diabetes mellitus type 2 was better than insulin treatment only.

scholarly journals EVALUATION OF OXIDATIVE STRESS AND ANTIOXIDANT STATUS BETWEEN TYPE II DIABETES PATIENTS AND HEALTHY POPULATIONS

2018 ◽  
Vol 11 (9) ◽  
pp. 264
Author(s):  
Sudharshan Reddy Nelli ◽  
Nilesh Kumar Sharma ◽  
Manoj Kumar P ◽  
Surya S Singh
Keyword(s):  
Blood Glucose ◽  
Type Ii Diabetes ◽  
Fasting Blood Glucose ◽  
Serum Levels ◽  
Diabetes Patient ◽  
Postprandial Blood Glucose ◽  
Control Group ◽  
Case Group ◽  
Type Ii ◽  
South Indian

Introduction: The aim of the present study is to profile the serum antioxidative enzymes, catalase (CAT), glutathione peroxidase (GPx), and superoxide dismutase (SOD) level in Type II diabetes mellitus patients in comparison to healthy volunteers in the South Indian population.Methodology: A prospective, observational, case–control study was conducted for 1 year with a total of 120 patients including 90 Type II diabetes patients (case group) and 30 healthy volunteers (control group). Blood was collected from these volunteers, and serum levels of CAT, GPx, and SOD were estimated. In addition, they were also monitored for the fasting blood glucose, glycated hemoglobin (HbA1c), and postprandial blood glucose. Data were statistically analyzed applying unpaired t-test and Pearson correlation with the statistical significance of p<0.05.Results: The diabetes patient group showed significant higher levels of glycated hemoglobin, fasting blood glucose and postprandial blood glucose (p<0.0001). There was asignificant lower level in the RBC levels of superoxide dismutase in case group compared to control group 3859.00±381.8 (mean+SD) and 5862.7±209.45 (mean+SD) Units per gram Hb, (t-value 27.35, p-Value <0.0001). Catalase and Glutathione peroxidase RBC levels also showed significant lower levels in the case group compared to the control group (catalase 212.7±19.08 (mean±SD) and 396.47±10.83 (mean±SD) Units per gram Hb; T value=50.07 and p<0.0001)(Glutathione peroxidase11.7 ±01.09 (mean +SD) and 18.6 ± 01.00 (mean +SD) Units per gram Hb; t value=30.26 and p<0.0001).Conclusion: A significant reduction in serum levels of antioxidative enzymes, CAT, GPx, and SOD was observed in the South Indian Type II diabetes patient population.

scholarly journals Plasma C-peptide and serum insulin antibodies in diabetic patients receiving pancreatic transplants

Diabetologia ◽  
1980 ◽  
Vol 19 (1) ◽  
pp. 25-30 ◽  
Author(s):  
J. �stman ◽  
P. Arner ◽  
C. G. Groth ◽  
R. Gunnarsson ◽  
Lise Heding ◽  
...  
Keyword(s):  
Serum Insulin ◽  
Insulin Antibodies ◽  
Diabetic Patients ◽  
C Peptide

scholarly journals The Application of Plasma 1,5-Anhydro-D-glucitol for Monitoring Type 2 Diabetic Patients

2005 ◽  
Vol 21 (3) ◽  
pp. 127-132 ◽  
Author(s):  
Marzena Dworacka ◽  
Hanna Winiarska
Keyword(s):  
Blood Glucose ◽  
Plasma Level ◽  
Multivariate Regression Analysis ◽  
Postprandial Blood Glucose ◽  
Effective Control ◽  
Diabetic Patients ◽  
Short Term ◽  
Type 2 Diabetic Patients ◽  
Type 2 Diabetic

Aim: Recent data have suggested that effective control of postprandial blood glucose can reduce the risk of macroangiopathic complications of diabetes, especially cardiovascular risk. 1,5-Anhydro-D-glucitol (1,5-AG) has been proposed as a marker of short-term hyperglycaemic excursions. We aimed to evaluate its usefulness in patients with type 2 diabetes and have attempted to indicate when 1,5-AG monitoring should be used in ordinary diabetes care settings. Methods: The study group consisted of 130 type 2 diabetic patients aged 36–69 years. 1,5-AG plasma level, HbA1c concentrations and daily glucose profile were measured. Mean blood glucose (MBG), M-value were calculated and maximal daily glycaemia (MxG) was established as indicators of short-term hyperglycaemic episodes. Results: 1,5-AG plasma level was negatively and HbA1c was positively correlated with fasting glycaemia (FG), MBG, M-value and MxG. Multivariate regression analysis revealed that 1,5-AG plasma level is determined by MxG only, while FG determined HbA1c concentration in blood. The analysis of 1,5-AG level and HbA1c distributions in well and poorly controlled patients revealed that persons with low HbA1c values may have decreased 1,5-AG plasma level. Conclusion: 1,5-AG plasma level monitoring is the useful method to identify well controlled, exclusively based on HbA1c levels type 2 diabetic patients with transient hyperglycaemia, accordingly patients at high risk of macroangiopathic complications.

Effect of an α-Glucosidase Inhibitor on Intestinal Fermentation and Faecal Lipids in Diabetic Patients

1993 ◽  
Vol 21 (5) ◽  
pp. 257-267 ◽  
Author(s):  
T Nakamura ◽  
K Takebe ◽  
K Kudoh ◽  
A Terada ◽  
Y Tandoh ◽  
...  
Keyword(s):  
Fatty Acids ◽  
Blood Glucose ◽  
Blood Glucose Level ◽  
Bile Acids ◽  
Glucose Level ◽  
Dependent Diabetes Mellitus ◽  
Diabetic Patients ◽  
Acid Excretion ◽  
Intestinal Transit Time ◽  
Glucosidase Inhibitor

Eight non-insulin-dependent diabetes mellitus patients, in whom oral hypoglycaemic agents were not effective, were treated with an α-glucosidase inhibitor, AO-128 (0.9 mg/day) for 6 months. After 6 months of treatment there was a statistically significant decrease in the blood glucose level 1 and 2 h postprandially. The 2 h blood glucose level was also significantly reduced after 2 months' treatment. The insulin and HbAlC levels after 2 and 6 months' treatment were lower than those before administration. Faecal weight, the frequency of bowel movements, the ratio of hydroxy fatty acids to total fatty acids, and faecal short-chain carboxylic acid content were all increased significantly during treatment. The initially hard stools became normal or soft, although no actual diarrhoea developed. Both faecal bile-acid excretion and the ratio of primary bile acids to total bile acids were increased significantly after 2 months, but they showed some recovery towards the pretreatment levels after 6 months' treatment. There was no distinct change in neutral sterol and fatty acid excretion. Breath hydrogen excretion showed a slight increase after treatment. These results suggest that intestinal fermentation was promoted and the intestinal transit time was shortened by AO-128 administration.

Sign in / Sign up

Export Citation Format

Share Document